오스코텍

주주 소통 간담회

November 26, 2025

Translating Science into Medicine

Oscotec Inc.

오스코텍 R&D 회사의 성과 및 미래 Pipeline

향후 1~2년마다 1개 L/O 목표

	기전/차별성	질병	Discovery	Lead Opt	Preclinical	Phase I	Phase II	
ADEL-Y01	• 타우 표적. 안전성 입증 • 차세대 항체 치료제	치매						단기 L/O
OCT-598	• 내성 핵심 경로 차단 EP2/4 이중 저해 • 내성항암제	고형암						
GCN-3545	• Geno-K 플랫폼 활용 • BIC ROCK2 억제제	폐섬유증						
OCT-648	• 섬유화 차단 • NUAK1 표적 억제제	만성신장질환						중기 L/O (`27 Q1~)
ONC1	• 내성 핵심 경로 차단 NUAK1/2 이중저해 • 내성항암제	고형암						
ONC2 ~ 5	• 신규 Modality, 혁신 플랫폼 등 공동개발	고형암						장기 Pipeline
DAC1 ~ 3	• 암세포 특이 효소 기반 • 안정성 강화 • 차세대 DAC 치료제	고형암						

* 상용화 파이프라인: 렉라자 (폐암). 내성 차단 기전을 갖춘 차세대 EGFR kinase 억제제
* 기타 Pipeline(추가 비용 투입 없이 기술이전): Cevidoplenib, 자가면역질환제(임상2상 완료), '26 Q4 L/O / Denfivontinib, 표적치료제(임상1상 완료), '26 Q2 L/O

R&D 로드맵 2020-2030



렉라자 이후의 오스코텍 내성항암제 전략





- 오스코텍 내성항암제 플랫폼
- 표적/물질 데이터베이스
- 내성 발달 기전 원천 억제
- 상용 약물 병용 전략
- 약물 안전성 – 신규 질환 분야 적용

Cevidoplenib

- History
  - One of the most advanced SYK-selective inhibitors worldwide (solvleplenib, BI-894416)
  - Proven competitive efficacy and superior tolerability in chronic ITP patients (2nd line) in global P2 study
- Current status
  - Initiated an investigator-initiated P2 study in newly diagnosed ITP patients (1st line)
  - Developed new crystal forms and formulation; patent application filed
  - High quality drug products manufactured; bioequivalence study planned
- Prospect
  - To explore new indications to maximize the potential value via partnering and external investment



Denfivontinib

- History
  - A potent FLT3/AXL dual inhibitor
  - Completed P1a as an injectable in AML patients in the US; confirmed efficacy in the subjects with FLT3-mutation
  - Strategic decision to halt further development in AML due to the lack of differentiation vs Xospata® (gilteritinib, Astellas)
  - Completed P1a as an oral pill in solid tumors in Korea; confirmed good exposure (PK) and safety
  - Strategic decision to deprioritize as OCT-598 advances
- Prospect
  - Potential collaboration/option deal on developing companion diagnostics for AML



Carter et al., Signal Transduction and Targeted Therapy, 2020

ADEL-Y01

- History
  - Acetyl K280-tau-targeting monoclonal antibody for Alzeheimer's disease
  - Joint development agreement with Adel, Inc. in 2020
  - Initiated P1 study in the US in 2023
- Current Status
  - Completed P1a single-ascending dose part in healthy volunteers; data to be presented in CTAD 2025
  - P1b multiple-ascending dose part in early AD patients underway
  - Protocol amendment to include prescreening (pTau 217) and dosing adjustment (q4w)
- Prospect
  - Potential licensing agreement with a global pharma before P2



Fitzpatrick et al., Nature 2017



OCT-598

- History
  - An EP2/4 dual antagonist, anticipated to help overcome cancer therapy resistance and immune evasion
  - In-licensed from Kanaph Therapeutics in 2022
  - Preclinical data presented at AACR 2023 and 2025
- Current Status
  - IND approved by FDA (June) and MFDS (November)
  - First-in-human dosing to start in December
- Prospect
  - P1b docetaxel combination to start in mid-2026 in multiple solid tumor types; a second combination regimen planned to start in-late 2026 (CRC or SCLC)
  - Trailblazing the development path for CTR programs to follow



Vision 2030

- The inventor, pioneer, and champion of **"anti-cancer-anti-resistance therapy"**
- The number one '**first-in-class'** drug discovery company in Korea
- Global reputation for;
  - Innovative pipeline
  - Breakthrough clinical results
  - **Multiple high-profile partnership deals**

History to Repeat Itself



Oscotec Inc.

Translating Science into Medicine

Oscotec Inc.